Related Experiment Video
Updated: Jun 22, 2026
09:54
Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
Published on: May 22, 2020
[Efficacy of rituximab therapy on diffuse large B-cell lymphoma with different Fcgamma RIIIA gene polymorphisms: a
Wei Zhang1, Xuan Wang, Ming-Hui Duan
1Department of Hematology, Peking Union Medical College Hospital, Peking Union Medical College, Beijing 100730, China.
Zhonghua Yi Xue Za Zhi
|July 2, 2009
Summary
FcgammaRIIIA gene variations impact rituximab effectiveness in diffuse large B-cell lymphoma (DLBCL). Patients with VV and VF FcgammaRIIIA types show better response to rituximab plus chemotherapy than FF type.
Area of Science:
- Pharmacogenomics
- Oncology
- Immunogenetics
Context:
- Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma.
- Rituximab, an anti-CD20 monoclonal antibody, is a cornerstone of DLBCL treatment.
- FcgammaRIIIA gene polymorphism is a potential factor influencing therapeutic outcomes.
Purpose:
- To investigate the association between FcgammaRIIIA gene polymorphism and the efficacy of rituximab-based chemotherapy in newly diagnosed DLBCL patients.
- To determine if specific FcgammaRIIIA genotypes predict treatment response.
Summary:
- This study analyzed FcgammaRIIIA polymorphisms (VV, FF, VF) in 34 newly diagnosed DLBCL patients treated with rituximab and CHOP chemotherapy.
- Overall response rates were 82% for VV, 83% for VF, and 60% for FF types.
- Patients with VV and VF genotypes demonstrated significantly higher response rates compared to the FF genotype (P = 0.04).
Impact:
- Findings suggest FcgammaRIIIA genotype can predict initial response to rituximab in DLBCL.
- This may inform personalized treatment strategies for DLBCL patients.
- Highlights the role of pharmacogenetics in optimizing anti-cancer therapies.
